Enhanced Potency meets Outstanding Manufacturability We are pleased to announce that we have successfully launched our new CHOFlow® technology for the production of afucosylated ADCC enhanced antibodies. CHOFlow® unifies excellent productivity rates and exceptionally stable and robust production processes of our CHOnamite® host cell line with a proven genetic glyco-optimization strategy. Read press release
weiterlesenSuccessful Cell Line Development for Strike Pharma We are pleased to announce that a production clone with excellent productivity and quality for Strike Pharma’s complex bi-specific antibody was successfully generated with productivity of 5.8 g/L perfectly sufficient for commercial manufacturing. The clone shows very stable expression and excellent upstream process performance. Strike Pharma’s proprietary Adaptable […]
weiterlesenFyoniBio and adivo GmbH sign Service Agreement We are pleased to announce the signing of a Service Agreement with adivo covering the generation of a production cell line for their canine therapeutic mAb candidate. For the project, FyoniBio will use its versatile CHOnamite® cell line development platform, that integrates a high-performance Transposase technology and comprises […]
weiterlesenStrike Pharma and FyoniBio sign a Master Service Agreement We are pleased to announce the signing of a Master Service Agreement with Strike Pharma. The project involves the use of the FyoniBio’s versatile CHOnamite® platform to develop and characterize a cell line for a novel, innovative bi-specific therapeutic mAb that has been produced using the […]
weiterlesenProteoNic and FyoniBio agree on cooperation We are pleased to share with you that we signed a license agreement with ProteoNic. FyoniBio includes the 2G Unic™ technology as an add-on to our proprietary vector technology platform in our CHOnamite® cell line development platform. By this we emphasize the scope for our clients’ cell line development […]
weiterlesenSuccessful Spin-out of FyoniBio to the newly formed entity FyoniBio GmBH We are very happy to inform you that from 1. February 2022, we continue the service business previously being part of Glycotope GmbH within the new entity FyoniBio GmbH. FyoniBio, now as part of Canton Biologics Group, a leading Chinese CDMO, will continue and […]
weiterlesenBioGenes and FyoniBio Enter a Scientific Cooperation We are happy to announce our collaboration with BioGenes which covers a broad range of services from antibody development to the analysis of clinical samples. The individual expertise of each company makes us ideal partners. The first customer projects are expected to start in the next couple of […]
weiterlesenCSL Behring and FyoniBio Partnering We are happy to have initiated a collaboration with CSL Behring research division for the use of the GlycoExpress (GEX®) technology for recombinant production of proteins. GlycoExpress® is a proven platform technology based on human cells for the production of biopharmaceuticals with a human glycosylation profile.
weiterlesen